Dopamine receptor D2 explained

Dopamine receptor D2, also known as D2R, is a protein that, in humans, is encoded by the DRD2 gene. After work from Paul Greengard's lab had suggested that dopamine receptors were the site of action of antipsychotic drugs, several groups, including those of Solomon H. Snyder and Philip Seeman used a radiolabeled antipsychotic drug to identify what is now known as the dopamine D2 receptor.[1] The dopamine D2 receptor is the main receptor for most antipsychotic drugs. The structure of DRD2 in complex with the atypical antipsychotic risperidone has been determined.[2] [3]

Function

D2 receptors are coupled to Gi subtype of G protein. This G protein-coupled receptor inhibits adenylyl cyclase activity.[4]

In mice, regulation of D2R surface expression by the neuronal calcium sensor-1 (NCS-1) in the dentate gyrus is involved in exploration, synaptic plasticity and memory formation.[5] Studies have shown potential roles for D2R in retrieval of fear memories in the prelimbic cortex[6] and in discrimination learning in the nucleus accumbens.[7]

In flies, activation of the D2 autoreceptor protected dopamine neurons from cell death induced by MPP+, a toxin mimicking Parkinson's disease pathology.[8]

While optimal dopamine levels favor D1R cognitive stabilization, it is the D2R that mediates the cognitive flexibility in humans.[9] [10] [11]

Isoforms

Alternative splicing of this gene results in three transcript variants encoding different isoforms.[12]

The long form (D2Lh) has the "canonical" sequence and functions as a classic post-synaptic receptor.[13] The short form (D2Sh) is pre-synaptic and functions as an autoreceptor that regulates the levels of dopamine in the synaptic cleft. Agonism of D2sh receptors inhibits dopamine release; antagonism increases dopaminergic release. A third D2(Longer) form differs from the canonical sequence where 270V is replaced by VVQ.

Active and inactive forms

D2R conformers are equilibrated between two full active (D2HighR) and inactive (D2LowR) states, while in complex with an agonist and antagonist ligand, respectively.

The monomeric inactive conformer of D2R in binding with risperidone was reported in 2018 (PDB ID: 6CM4). However, the active form which is generally bound to an agonist, is not available yet and in most of the studies the homology modeling of the structure is implemented. The difference between the active and inactive of G protein-coupled receptor is mainly observed as conformational changes at the cytoplasmic half of the structure, particularly at the transmembrane domains (TM) 5 and 6. The conformational transitions occurred at the cytoplasmic ends are due to the coupling of G protein to the cytoplasmic loop between the TM 5 and 6.[14]

It was observed that either D2R agonist or antagonist ligands revealed better binding affinities inside the ligand-binding domain of the active D2R in comparison with the inactive state. It demonstrated that ligand-binding domain of D2R is affected by the conformational changes occurring at the cytoplasmic domains of the TM 5 and 6. In consequence, the D2R activation reflects a positive cooperation on the ligand-binding domain.

In drug discovery studies in order to calculate the binding affinities of the D2R ligands inside the binding domain, it's important to work on which form of D2R. It's known that the full active and inactive states are recommended to be used for the agonist and antagonist studies, respectively.

Any disordering in equilibration of D2R states, which causes problems in signal transferring between the nervous systems, may lead to diverse serious disorders, such as schizophrenia,[15] autism {{citation needed}} and Parkinson's disease {{citation needed}}. In order to assist in the management of these conditions, equilibration between the D2R states is controlled by implementing of agonist and antagonist D2R ligands {{citation needed}}. In most cases, it was observed that the problems regarding the D2R states may have genetic roots and are controlled by drug therapies {{citation needed}}. So far, there is no certain treatment for these mental disorders.

Allosteric pocket and orthosteric pocket

There is an orthosteric binding site (OBS), as well as a secondary binding pocket (SBP) on the dopamine 2 receptor, and interaction with the SBP is a requirement for allosteric pharmacology. The compound SB269652 is a negative allosteric modulator of the D2R.[16]

Oligomerization of D2R

It was observed that D2R exists in dimeric forms or higher order oligomers.[17] There are some experimental and molecular modeling evidences that demonstrated the D2R monomers cross link from their TM 4 and TM 5 to form dimeric conformers.[18] [19]

Genetics

Allelic variants:

Some researchers have previously associated the polymorphism Taq 1A (rs1800497) to the DRD2 gene.However, the polymorphism resides in exon 8 of the ANKK1 gene.[23] DRD2 TaqIA polymorphism has been reported to be associated with an increased risk for developing motorfluctuations but not hallucinations in Parkinson's disease.[24] [25] A splice variant in Dopamine receptor D2(rs1076560) was found to be associated with limb truncal Tardive dyskinesia and diminished expression factor of Positive and Negative Syndrome Scale (PANSS) in schizophrenia subjects.[26]

Ligands

Most of the older antipsychotic drugs such as chlorpromazine and haloperidol are antagonists for the dopamine D2 receptor, but are, in general, very unselective, at best selective only for the "D2-like family" receptors and so binding to D2, D3 and D4, and often also to many other receptors such as those for serotonin and histamine, resulting in a range of side-effects and making them poor agents for scientific research. In similar manner, older dopamine agonists used for Parkinson's disease such as bromocriptine and cabergoline are poorly selective for one dopamine receptor over another, and, although most of these agents do act as D2 agonists, they affect other subtypes as well. Several selective D2 ligands are, however, now available, and this number is likely to increase as further research progresses.

Agonists

Partial agonists

Antagonists

D2sh selective (presynaptic autoreceptors)

Allosteric modulators

Heterobivalent ligands

Dual D2AR/ A2AAR ligands

Functionally selective ligands

Protein–protein interactions

The dopamine receptor D2 has been shown to interact with EPB41L1,[45] PPP1R9B[46] and NCS-1.[47]

Receptor oligomers

The D2 receptor forms receptor heterodimers in vivo (i.e., in living animals) with other G protein-coupled receptors; these include:[48]

The D2 receptor has been shown to form heterodimers in vitro (and possibly in vivo) with DRD3,[49] DRD5,[50] and 5-HT2A.[51]

See also

External links

Notes and References

  1. Madras BK . History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia . Journal of the History of the Neurosciences . 22 . 1 . 62–78 . 2013 . 23323533 . 10.1080/0964704X.2012.678199 . 12002684 .
  2. Bryan Roth . Wang S, Che T, Levit A, Shoichet BK, Wacker D, Roth BL . Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone . Nature . 555 . 7695 . 269–273 . March 2018 . 29466326 . 5843546 . 10.1038/nature25758 . 2018Natur.555..269W .
  3. Web site: NIMH » Molecular Secrets Revealed: Antipsychotic Docked in its Receptor. www.nimh.nih.gov. 29 January 2018 . en. 2018-11-26.
  4. Usiello A, Baik JH, Rougé-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E . Distinct functions of the two isoforms of dopamine D2 receptors . Nature . 408 . 6809 . 199–203 . November 2000 . 11089973 . 10.1038/35041572 . 2000Natur.408..199U . 4354606 .
  5. Saab BJ, Georgiou J, Nath A, Lee FJ, Wang M, Michalon A, Liu F, Mansuy IM, Roder JC . NCS-1 in the dentate gyrus promotes exploration, synaptic plasticity, and rapid acquisition of spatial memory . Neuron . 63 . 5 . 643–56 . September 2009 . 19755107 . 10.1016/j.neuron.2009.08.014 . 5321020 . free .
  6. Madsen HB, Guerin AA, Kim JH . Investigating the role of dopamine receptor- and parvalbumin-expressing cells in extinction of conditioned fear . Neurobiology of Learning and Memory . 145 . 7–17 . November 2017 . 28842281 . 10.1016/j.nlm.2017.08.009 . 26875742 .
  7. Iino Y, Sawada T, Yamaguchi K, Tajiri M, Ishii S, Kasai H, Yagishita S . Dopamine D2 receptors in discrimination learning and spine enlargement . Nature . 579 . 7800 . 555–560 . March 2020 . 32214250 . 10.1038/s41586-020-2115-1 . 2020Natur.579..555I . 213162661 .
  8. Wiemerslage L, Schultz BJ, Ganguly A, Lee D . Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture . Journal of Neurochemistry . 126 . 4 . 529–40 . August 2013 . 23452092 . 3737274 . 10.1111/jnc.12228 .
  9. Cameron IG, Wallace DL, Al-Zughoul A, Kayser AS, D'Esposito M . Effects of tolcapone and bromocriptine on cognitive stability and flexibility . Psychopharmacology . 235 . 4 . 1295–1305 . April 2018 . 29427081 . 5869902 . 10.1007/s00213-018-4845-4 . primary .
  10. Yee DM, Braver TS . Interactions of Motivation and Cognitive Control . Current Opinion in Behavioral Sciences . 19 . 83–90 . February 2018 . 30035206 . 6051692 . 10.1016/j.cobeha.2017.11.009 .
  11. Persson J, Stenfors C . Superior cognitive goal maintenance in carriers of genetic markers linked to reduced striatal D2 receptor density (C957T and DRD2/ANKK1-TaqIA) . PLOS ONE. 13 . 8 . e0201837 . 2018 . 30125286 . 6101371 . 10.1371/journal.pone.0201837 . 2018PLoSO..1301837P . free .
  12. Web site: Entrez Gene: DRD2 dopamine receptor D2.
  13. Beaulieu JM, Gainetdinov RR . The physiology, signaling, and pharmacology of dopamine receptors . Pharmacological Reviews . 63 . 1 . 182–217 . March 2011 . 21303898 . 10.1124/pr.110.002642 . 2545878 .
  14. Salmas RE, Yurtsever M, Stein M, Durdagi S . Modeling and protein engineering studies of active and inactive states of human dopamine D2 receptor (D2R) and investigation of drug/receptor interactions . Molecular Diversity . 19 . 2 . 321–32 . May 2015 . 25652238 . 10.1007/s11030-015-9569-3 . 1636767 .
  15. Seeman P, Chau-Wong M, Tedesco J, Wong K . Brain receptors for antipsychotic drugs and dopamine: direct binding assays . Proceedings of the National Academy of Sciences of the United States of America . 72 . 11 . 4376–80 . November 1975 . 1060115 . 388724 . 10.1073/pnas.72.11.4376 . 1975PNAS...72.4376S . free .
  16. Draper-Joyce CJ, Michino M, Verma RK, Klein Herenbrink C, Shonberg J, Kopinathan A, Scammells PJ, Capuano B, Thal DM, Javitch JA, Christopoulos A, Shi L, Lane JR . 2 receptor . Biochemical Pharmacology . 148 . 315–328 . February 2018 . 29325769 . 5800995 . 10.1016/j.bcp.2018.01.002 .
  17. Armstrong D, Strange PG . Dopamine D2 receptor dimer formation: evidence from ligand binding . The Journal of Biological Chemistry . 276 . 25 . 22621–9 . June 2001 . 11278324 . 10.1074/jbc.M006936200 . free .
  18. Guo W, Shi L, Javitch JA . The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer . The Journal of Biological Chemistry . 278 . 7 . 4385–8 . February 2003 . 12496294 . 10.1074/jbc.C200679200 . free .
  19. Durdagi S, Salmas RE, Stein M, Yurtsever M, Seeman P . Binding Interactions of Dopamine and Apomorphine in D2High and D2Low States of Human Dopamine D2 Receptor Using Computational and Experimental Techniques . EN . ACS Chemical Neuroscience . 7 . 2 . 185–95 . February 2016 . 26645629 . 10.1021/acschemneuro.5b00271 .
  20. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV . Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor . Human Molecular Genetics . 12 . 3 . 205–16 . February 2003 . 12554675 . 10.1093/hmg/ddg055 . free .
  21. Arinami T, Gao M, Hamaguchi H, Toru M . A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia . Human Molecular Genetics . 6 . 4 . 577–82 . April 1997 . 9097961 . 10.1093/hmg/6.4.577 . free .
  22. Glatt SJ, Faraone SV, Tsuang MT . DRD2 -141C insertion/deletion polymorphism is not associated with schizophrenia: results of a meta-analysis . American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics . 128B . 1 . 21–3 . July 2004 . 15211624 . 10.1002/ajmg.b.30007 . 330601 .
  23. Lucht M, Rosskopf D . Comment on "Genetically determined differences in learning from errors" . Science . 321 . 5886 . 200; author reply 200 . July 2008 . 18621654 . 10.1126/science.1155372 . 2008Sci...321..200L . 263582444 .
  24. Wang J, Liu ZL, Chen B . Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD . Neurology . 56 . 12 . 1757–9 . June 2001 . 11425949 . 10.1212/WNL.56.12.1757 . 38421055 .
  25. Wang J, Zhao C, Chen B, Liu ZL . Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease . Neuroscience Letters . 355 . 3 . 193–6 . January 2004 . 14732464 . 10.1016/j.neulet.2003.11.006 . 44740438 .
  26. Punchaichira TJ, Kukshal P, Bhatia T, Deshpande SN, Thelma BK . The effect of rs1076560 (DRD2) and rs4680 (COMT) on tardive dyskinesia and cognition in schizophrenia subjects. Psychiatric Genetics . 30 . 5 . 125–135 . 2020 . 32931693 . 10.1097/YPG.0000000000000258. 221718209. 10111058 .
  27. Web site: Clinical Pharmacology for Abilify . 2010-01-21 . RxList.com . 2010-01-21.
  28. Seeman P, Guan HC, Hirbec H . Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil . Synapse . 63 . 8 . 698–704 . August 2009 . 19391150 . 10.1002/syn.20647 . 17758902 .
  29. Holmes IP, Blunt RJ, Lorthioir OE, Blowers SM, Gribble A, Payne AH, Stansfield IG, Wood M, Woollard PM, Reavill C, Howes CM, Micheli F, Di Fabio R, Donati D, Terreni S, Hamprecht D, Arista L, Worby A, Watson SP . The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure . Bioorganic & Medicinal Chemistry Letters . 20 . 6 . 2013–6 . March 2010 . 20153647 . 10.1016/j.bmcl.2010.01.090 .
  30. Giacomelli S, Palmery M, Romanelli L, Cheng CY, Silvestrini B . Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro . Life Sciences . 63 . 3 . 215–22 . 1998 . 9698051 . 10.1016/S0024-3205(98)00262-8 .
  31. Seeman P, Caruso C, Lasaga M . Memantine agonist action at dopamine D2High receptors . Synapse . 62 . 2 . 149–53 . February 2008 . 18000814 . 10.1002/syn.20472 . 20494427 . 11336/108388 . free .
  32. Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G, Caloro M, Telesforo CL, Caltagirone SS, Panaccione I, Simonetti A, Demontis F, Serra G, Girardi P . 6 . The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence . CNS Drugs . 26 . 8 . 663–90 . August 2012 . 22784018 . 10.2165/11634390-000000000-00000 . 21597978 .
  33. Wang GJ, Volkow ND, Thanos PK, Fowler JS . Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review . Journal of Addictive Diseases . 23 . 3 . 39–53 . 2004 . 15256343 . 10.1300/J069v23n03_04 . 14589783 .
  34. Huang R, Griffin SA, Taylor M, Vangveravong S, Mach RH, Dillon GH, Luedtke RR . The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition . Pharmacology . 92 . 1–2 . 84–9 . 2013 . 23942137 . 10.1159/000351971 . 33761631 .
  35. Lechin F, van der Dijs B, Jara H, Orozco B, Baez S, Benaim M, Lechin M, Lechin A . Effects of buspirone on plasma neurotransmitters in healthy subjects . Journal of Neural Transmission . 105 . 6–7 . 561–73 . 1998 . 9826102 . 10.1007/s007020050079 . 12858061 .
  36. Agnati LF, Ferré S, Genedani S, Leo G, Guidolin D, Filaferro M, Carriba P, Casadó V, Lluis C, Franco R, Woods AS, Fuxe K . Allosteric modulation of dopamine D2 receptors by homocysteine . Journal of Proteome Research . 5 . 11 . 3077–83 . November 2006 . 17081059 . 10.1021/pr0601382 . 10.1.1.625.26 .
  37. Beyaert MG, Daya RP, Dyck BA, Johnson RL, Mishra RK . PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia . European Neuropsychopharmacology . 23 . 3 . 253–62 . March 2013 . 22658400 . 10.1016/j.euroneuro.2012.04.010 . 25146332 .
  38. Lane JR, Donthamsetti P, Shonberg J, Draper-Joyce CJ, Dentry S, Michino M, Shi L, López L, Scammells PJ, Capuano B, Sexton PM, Javitch JA, Christopoulos A . A new mechanism of allostery in a G protein-coupled receptor dimer . Nature Chemical Biology . 10 . 9 . 745–52 . September 2014 . 25108820 . 4138267 . 10.1038/nchembio.1593 .
  39. Maggio R, Scarselli M, Capannolo M, Millan MJ . Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation . European Neuropsychopharmacology . 25 . 9 . 1470–9 . September 2015 . 25453482 . 10.1016/j.euroneuro.2014.09.016 . 25513707 .
  40. Silvano E, Millan MJ, Mannoury la Cour C, Han Y, Duan L, Griffin SA, Luedtke RR, Aloisi G, Rossi M, Zazzeroni F, Javitch JA, Maggio R . The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors . Molecular Pharmacology . 78 . 5 . 925–34 . November 2010 . 20702763 . 2981362 . 10.1124/mol.110.065755 .
  41. Rossi M, Fasciani I, Marampon F, Maggio R, Scarselli M . 3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs . Molecular Pharmacology . 91 . 6 . 586–594 . June 2017 . 28265019 . 5438131 . 10.1124/mol.116.107607 .
  42. Matera C, Pucci L, Fiorentini C, Fucile S, Missale C, Grazioso G, Clementi F, Zoli M, De Amici M, Gotti C, Dallanoce C . Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization . European Journal of Medicinal Chemistry . 101 . 367–83 . August 2015 . 26164842 . 10.1016/j.ejmech.2015.06.039 .
  43. Kampen S, Duy Vo D, Zhang X, Panel N, Yang Y, Jaiteh M, Matricon P, Svenningsson P, Brea J, Loza MI, Kihlberg J, Carlsson J . 6 . Structure-Guided Design of G-Protein-Coupled Receptor Polypharmacology . Angewandte Chemie . 60 . 33 . 18022–18030 . August 2021 . 33904641 . 8456950 . 10.1002/anie.202101478 .
  44. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetsel WC, Caron MG, Javitch JA, Roth BL, Jin J . Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy . Proceedings of the National Academy of Sciences of the United States of America . 108 . 45 . 18488–93 . November 2011 . 22025698 . 3215024 . 10.1073/pnas.1104807108 . 2011PNAS..10818488A . free .
  45. Binda AV, Kabbani N, Lin R, Levenson R . D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N . Molecular Pharmacology . 62 . 3 . 507–13 . September 2002 . 12181426 . 10.1124/mol.62.3.507 . 19901660 .
  46. Smith FD, Oxford GS, Milgram SL . Association of the D2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein . The Journal of Biological Chemistry . 274 . 28 . 19894–900 . July 1999 . 10391935 . 10.1074/jbc.274.28.19894 . free .
  47. Kabbani N, Negyessy L, Lin R, Goldman-Rakic P, Levenson R . Interaction with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine receptor . The Journal of Neuroscience . 22 . 19 . 8476–86 . October 2002 . 12351722 . 6757796 . 10.1523/JNEUROSCI.22-19-08476.2002 .
  48. Beaulieu JM, Espinoza S, Gainetdinov RR . Dopamine receptors – IUPHAR Review 13 . British Journal of Pharmacology . 172 . 1 . 1–23 . January 2015 . 25671228 . 4280963 . 10.1111/bph.12906 .
  49. Maggio R, Millan MJ . Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance . Current Opinion in Pharmacology . 10 . 1 . 100–7 . February 2010 . 19896900 . 10.1016/j.coph.2009.10.001 .
  50. Hasbi A, O'Dowd BF, George SR . Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms . Current Opinion in Pharmacology . 10 . 1 . 93–9 . February 2010 . 19897420 . 2818238 . 10.1016/j.coph.2009.09.011 .
  51. Albizu L, Holloway T, González-Maeso J, Sealfon SC . Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors . Neuropharmacology . 61 . 4 . 770–7 . September 2011 . 21645528 . 3556730 . 10.1016/j.neuropharm.2011.05.023 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dopamine receptor D2".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.